Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest quarterly earnings
Latest quarterly earnings
Latest investor presentation
Latest investor presentation
Latest clinical presentation
Latest clinical presentation
Latest publications
Our research
Annual report
Annual report
NASDAQ:NVAX
Loading data...
Stock details
Latest press releasesEvents & presentationsReports & financialsSEC filingsStock details & analyst coverage
Oct 9, 2024
COVID-19

Novavax's Updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine Receives Authorization in the EU

Read full article
Download
Oct 7, 2024
Statement
COVID-19

Novavax Update: Where to Find Our COVID-19 Vaccine

Read full article
Download
Sep 25, 2024
Corporate and finance

Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development

Read full article
Download
All press releases
Our ESG Approach

Discover the steps we have taken in the areas of access, governance, environment, and diversity and find our latest sustainability reports.

Learn more
child holding plant
Governance documents
Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription
Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at [email protected]

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.

Graph icon